SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-018124
Filing Date
2023-11-08
Accepted
2023-11-08 07:45:37
Documents
45
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20230930x10q.htm   iXBRL 10-Q 1075612
2 EX-31.1 tmb-20230930xex31d1.htm EX-31.1 16129
3 EX-31.2 tmb-20230930xex31d2.htm EX-31.2 16137
4 EX-32.1 tmb-20230930xex32d1.htm EX-32.1 8285
5 EX-32.2 tmb-20230930xex32d2.htm EX-32.2 8847
  Complete submission text file 0001558370-23-018124.txt   3911497

Data Files

Seq Description Document Type Size
6 EX-101.SCH tmb-20230930.xsd EX-101.SCH 25860
7 EX-101.CAL tmb-20230930_cal.xml EX-101.CAL 18907
8 EX-101.DEF tmb-20230930_def.xml EX-101.DEF 101770
9 EX-101.LAB tmb-20230930_lab.xml EX-101.LAB 265914
10 EX-101.PRE tmb-20230930_pre.xml EX-101.PRE 194212
39 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20230930x10q_htm.xml XML 514763
Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Filer) CIK: 0001875558 (see all company filings)

IRS No.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41264 | Film No.: 231386005
SIC: 2834 Pharmaceutical Preparations